Paul K Whelton
Overview
Explore the profile of Paul K Whelton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
321
Citations
29570
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Peacock E, Muntner P, Craig L, Silver J, Mills K, Chen J, et al.
Med Clin North Am
. 2024 Apr;
107(6S):e39-e52.
PMID: 38609280
Uncontrolled hypertension and low antihypertensive medication adherence remain significant clinical challenges. There is a critical need to detect meaningful change in adherence in clinical settings. The authors determined that a...
12.
Foti K, Coresh J, Whelton P, Matsushita K, Hardy S, Reynolds K, et al.
Hypertension
. 2024 Apr;
81(6):1356-1364.
PMID: 38567509
Background: It is unknown whether maintaining normal blood pressure (BP) from middle to older age is associated with improved health outcomes. Methods: We estimated the proportion of Atherosclerosis Risk in...
13.
Olowoyo P, Dzudie A, Okekunle A, Obiako R, Mocumbi A, Beheiry H, et al.
J Hum Hypertens
. 2024 Feb;
38(3):193-199.
PMID: 38424209
The prevalence of hypertension, the commonest risk factor for preventable disability and premature deaths, is rapidly increasing in Africa. The African Control of Hypertension through Innovative Epidemiology, and a Vibrant...
14.
Bansal S, Boucher R, Shen J, Wei G, Chertow G, Whelton P, et al.
Clin J Am Soc Nephrol
. 2024 Jan;
19(5):620-627.
PMID: 38262377
Background: In a post hoc analysis, we examined whether postrandomization diuretics use can explain and/or mediate the beneficial effects of intensive systolic BP lowering on cardiovascular disease and all-cause mortality...
15.
Olowoyo P, Barango P, Moran A, Williams B, Whelton P, Owolabi M
Lancet Glob Health
. 2024 Jan;
12(2):e192-e193.
PMID: 38245107
No abstract available.
16.
Drawz P, Lenoir K, Rai N, Rastogi A, Chu C, Rahbari-Oskoui F, et al.
Clin J Am Soc Nephrol
. 2023 Oct;
19(2):213-223.
PMID: 37883184
Background: Intensive BP lowering in the Systolic Blood Pressure Intervention Trial (SPRINT) produced acute decreases in kidney function and higher risk for AKI. We evaluated the effect of intensive BP...
17.
Khan T, Moran A, Perel P, Whelton P, Brainin M, Feigin V, et al.
Front Public Health
. 2023 Aug;
11:1146441.
PMID: 37554732
Cardiovascular diseases (CVD), principally ischemic heart disease (IHD) and stroke, are the leading causes of death (18. 6 million deaths annually) and disability (393 million disability-adjusted life-years lost annually), worldwide....
18.
Di Federico S, Filippini T, Whelton P, Cecchini M, Iamandii I, Boriani G, et al.
Hypertension
. 2023 Jul;
80(10):1961-1969.
PMID: 37522179
Background: Alcohol consumption may increase blood pressure but the details of the relationship are incomplete, particularly for the association at low levels of alcohol consumption, and no meta-analyses are available...
19.
Martinez R, Soliz P, Campbell N, Lackland D, Whelton P, Ordunez P
Rev Panam Salud Publica
. 2023 Jul;
47:e124.
PMID: 37497153
Objective: To quantify the association between the prevalence of population hypertension control and ischemic heart disease (IHD) and stroke mortality in 36 countries of the Americas from 1990 to 2019....
20.
Derington C, Bress A, Berchie R, Herrick J, Shen J, Ying J, et al.
Am J Hypertens
. 2023 Jun;
36(9):498-508.
PMID: 37378472
Background: The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated an intensive (<120 mm Hg) vs. standard (<140 mm Hg) systolic blood pressure (SBP) goal lowered cardiovascular disease (CVD) risk. Estimating...